Dabigatran Is Not a Direct Xa Inhibitor
Journal of the American College of Cardiology, 2012 Basra et al. ([1][1]) wrote a timely state-of-the-art paper on “safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease” in the Journal .
openaire +3 more sources
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
New England Journal of Medicine, 2017 C. Cannon +17 more
semanticscholar +1 more source
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial: reply to a rebuttal [PDF]
, 2011 Karl‐Heinz Liesenfeld +9 more
openalex +1 more source
Anticoagulant Options — Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran [PDF]
, 2011 B. Nhi Beasley +2 more
openalex +1 more source
International Journal of Emergency MedicineDabigatran is an oral anticoagulant that is mainly renally excreted. Despite its efficacy in preventing thromboembolic events, concerns arise regarding bleeding complications in patients with acute kidney injury. Idarucizumab is its specific antidote and
Rafik Matbouli +5 more
doaj +1 more source
Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? [PDF]
, 2014 Al-Khatib, SM +15 more
core +1 more source
The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin
, 2009 A. John Camm
openalex +1 more source
Lack of an antagonist to reverse the action of dabigatran [PDF]
, 2011 Oscar M.P. Jolobe
openalex +1 more source
Dabigatran Reversal with Idarucizumab
New England Journal of Medicine, 2017 Pollack, Charles V. +2 more
openaire +7 more sources